On Sunday, Cogent Biosciences, Inc. (NASDAQ: COGT ) revealed updated clinical results from the Open Label Extension (OLE) portion of the SUMMIT trial of bezuclastinib in patients with non-advanced systemic mastocytosis .
Non-advanced systemic mastocytosis is a rare disease that involves mast cell buildup in tissues and organs .
Updated clinical data presented at the American Society of Hematology Annual Meeting & Exposition show:
Pharmacodynamic Data: Bezuclastinib showed rapid, deep, and sustained reductions in serum tryptase over 24 weeks of treatment, including:
Safety Data
SUMMIT Enrollment Update
Price Action: COGT stock is up 10.60% at $9.83 at the last check on Monday.
Read Next:
UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily , plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets.
Get the latest stock analysis from Benzinga?
This article Why Is Cogent Biosciences Stock Trading Higher On Monday? originally appeared on Benzinga.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.